Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NWPT-SM32300
- Development stage
- Unknown
- Lead developer
- NW PharmaTech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NWPT-SM32300 is an investigational, pharmaceutical-grade oral cannabidiol (CBD) formulation developed by NW-Pharmatech. It utilizes a high-loading micellar delivery system formulated as a softgel capsule to improve the oral bioavailability and absorption consistency of CBD. NWPT-SM32300 is under clinical development as a monotherapy for the treatment of acute schizophrenia and clinical high risk for psychosis (CHR-P). Unlike traditional antipsychotics that primarily target dopamine D2 receptors, CBD acts through a multi-target mechanism of action, including negative allosteric modulation of cannabinoid receptors (CB1 and CB2), agonism of serotonin 5-HT1A and TRPV1 receptors, antagonism of GPR55, and inhibition of fatty acid amide hydrolase (FAAH) to enhance endocannabinoid signaling.
- Other names
- CBDcannabidiol
02
Targets
CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))TRPV1 (Transient receptor potential cation channel subfamily V member 1)FAAH
Beyond the preview
Go deeper on NWPT-SM32300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NWPT-SM32300.